- Home
- VRDN
as 05-09-2025 4:00pm EST
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 1.6B | IPO Year: | N/A |
| Target Price: | $36.82 | AVG Volume (30 days): | 887.1K |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.90 - $27.20 | Next Earning Date: | 05-06-2025 |
| Revenue: | $302,000 | Revenue Growth: | 4.86% |
| Revenue Growth (this year): | -34.34% | Revenue Growth (next year): | 20553.29% |
Latest Viridian Therapeutics Inc. News
VRDN Breaking Stock News: Dive into VRDN Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)
Simply Wall St.
3 days ago
Viridian Therapeutics First Quarter 2025 Earnings: Beats Expectations
Business Wire
4 days ago
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results
Business Wire
8 days ago
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
a month ago
Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors
Business Wire
2 months ago
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
2 months ago
Viridian Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
Business Wire
2 months ago
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
Compare VRDN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRDN Viridian Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.